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• Both OAC treatment and withholding 
carry the potential for catastrophic 
outcomes
• The gravity of this decision requires 
special attention to patient education 
and involvement in the decision-
making process, including:
– Shared-decision making tools
– Visual aids for patient education
– Usage of composite risk / benefit, “Net 
clinical benefit,” measures in both 
physician and patient-directed 
education
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REFERENCES
• Demographics
– 205 of 526 patients eligible for inclusion
– Mean age of 81 years
– 54% female
• Plurality of patients (42.9%) denied 
OAC due to bleed or fall risk
– Inconsistent with current guidelines
– Modifiable risk factors
– Targets for physician- and patient-
directed educational interventions
• Physicians have legitimate 
concerns and are accurately 
identifying patients at higher risk of 
bleeding
– Increased use of shared decision 
making may assist proper 
navigation of risks / benefits of 
OAC 
• Low usage rate of left atrial 
appendage occlusion surgery  
• Retrospective chart review of current 
LVHN patients
• Inclusion criteria: 
– History of atrial fibrillation 
• ICD-10: I48.0 – I48.4, I48.9
• Documented diagnostic 
evidence of AF
– History of stroke
• ICD-10: I63.0 – I63.9
• Exclusion criteria: 
– Currently prescribed oral 
anticoagulant medication (OAC)
– Less than one month of 
documented clinical history
– Greater than twelve months since 
last documented clinical 
encounter
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Problem Statement
• Atrial fibrillation (AF) is an abnormal 
heart rhythm defined by irregular, 
uncoordinated beating of the atria1
• AF disrupts cardiac blood flow, leading 
to the formation of thrombi that can then 
embolize, occluding cerebral blood flow2
• Untreated AF confers a fivefold 
increased risk of ischemic stroke3
• Treatment with anticoagulant medication 
reduces stroke risk; but increases 
bleeding risk4,5
• Evidence-based guidelines exist to 
inform treatment decisions5.
• Only a fraction of eligible patients 
receive appropriate treatment in 
accordance with guidelines6
The purpose of the present study is to assess, via 
review of physician-authored medical documentation, 
the reasons for prescriber avoidance of 
anticoagulation in patients with histories of both 
atrial fibrillation and stroke, and the clinical 
characteristics of these patients.
Table 1: Patient Characteristics - Comorbidities of patient population
CKD: Chronic Kidney Disease, CHF: Congestive Heart Failure, ICH: Intracerebral 
hemorrhage, SDH: Subdural hematoma, SAH: Subarachnoid hemorrhage
Table 2: Reasons for Withholding OAC Medication.
LAA: Left atrial appendage, Declined: Patient or caregiver declined treatment, Comfort 
measures: End-of-life or hospice care, AF due to another medical…: AF due to specific 
time-limited or treatable condition
Table 3: Risk Stratification
Compares CHA₂DS₂-VASc and HAS-BLED scores of patients deemed bleed risks, fall risks, 
and those who declined treatment with the cohort as a whole.
Table 4: Health System-related cohort data 
Echocardiogram: Percentage of patients receiving echocardiogram within 6 months of 
AF diagnosis, Medication Bleed Risk: Percentage of patients on medications that 
increase bleed risk, PCP Follow-up: Percentage of patients who follow-up with a 
primary care provider (PCP) following AF diagnosis, Cardiology Follow-up: Percentage 
of patients seen by outpatient cardiology following AF diagnosis Lost to Follow-up: 
Percentage of patients with no documented clinical encounters for 60 days following 
their last encounter
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